Safe Readministration of Intravenous Thrombolysis in Recurrent Basilar Thrombosis.

Safe Readministration of Intravenous Thrombolysis in Recurrent Basilar Thrombosis.

Khan Alina; Itrat Ahmed

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

2018

2018-03

We report a patient who had recurrence of stroke in the basilar artery territory because of repeat thrombosis, and was administered intravenous recombinant tissue plasminogen activator (IV-rtPA) twice within a span of 3 weeks without any adverse events, with radiological evidence of successful thrombolysis. Because of minor and improving stroke symptoms with IV-rtPA, endovascular therapy was not performed and there was radiological evidence of recanalization with IV-rtPA alone. This report adds to the very limited literature on the topic demonstrating safe and successful use of repeat IV thrombolysis following a previous recent stroke.

Aged; Basilar Artery; Basilar Artery – Drug Effects; Basilar Artery – Physiopathology; Basilar Artery/diagnostic imaging/*drug effects/physiopathology; Cerebral Angiography – Methods; Cerebral Angiography/methods; Computed Tomography Angiography; Drug Administration Schedule; Fibrinolytic Agents – Administration and Dosage; Fibrinolytic Agents – Adverse Effects; Fibrinolytic Agents/*administration & dosage/adverse effects; Humans; Infusions; Intracranial Thrombosis; Intracranial Thrombosis – Drug Therapy; Intracranial Thrombosis – Physiopathology; Intracranial Thrombosis/diagnostic imaging/*drug therapy/physiopathology; Intravenous; Magnetic Resonance Imaging; Male; medication safety; Recombinant Proteins – Administration and Dosage; Recombinant Proteins/administration & dosage; Recurrence; recurrent stroke; Repeat Procedures; Retreatment; thrombolysis; Thrombolytic Therapy – Adverse Effects; Thrombolytic Therapy – Methods; Thrombolytic Therapy/adverse effects/*methods; Thrombosis; Time Factors; Tissue Plasminogen Activator – Administration and Dosage; Tissue Plasminogen Activator – Adverse Effects; Tissue Plasminogen Activator/*administration & dosage/adverse effects; Treatment Outcome; Treatment Outcomes

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

e48–e49

3

27